Piper Jaffray reiterates their Buy rating and maintains their $78 price target on Myriad Genetics (NASDAQ: MYGN), calling the stock ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE